• 作者：Laura W. Musselwhite^a ; ^b ; Bruno B. Andrade^c ; ^d ; ^e ; Susan S. Ellenberg^f ; Ann Tierney^f ; Pablo F. Belaunzaran-Zamudio^g ; ^h ; Adam Rupertⁱ ; Michael M. Lederman^j ; Ian Sanne^k ; Juan G. Sierra Madero^g ; Irini Sereti^a ; ^{isereti@niaid.nih.gov" class="auth_mail" title="E-mail the corresponding author}
• 关键词：IRIS ; HIV ; Biomarker ; Vitamin D ; d-Dimer ; Inflammatory cytokine
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：4
• 期：Complete
• 页码：115-123
• 全文大小：1069 K

•

We compared immunologic patterns in 267 AIDS patients in South Africa and Mexico based on IRIS development after starting ART

•

Prior to starting ART, elevated markers of Th1 response, monocyte activation, coagulation and low vitamin D predicted IRIS

•

Our results support future IRIS prevention studies that aim to decrease immune activation and increase vitamin D levels

Over 36 million people are now infected with HIV, and almost all reside in developing countries. HIV antiretroviral treatment saves lives by promoting immune system recovery. Unfortunately, treatment can cause a serious condition called immune reconstitution inflammatory syndrome (IRIS) in up to one-third of patients. Experts think IRIS results from unbalanced recovery of the immune system and it is difficult to predict which patients will develop it. We found that prior to starting treatment, low vitamin D and a unique immunological pattern predicted risk. Our results suggest that IRIS prevention studies should focus on decreasing inflammation and increasing vitamin D levels.